Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease.
Gori
A
A
Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy.
Rossi
M C
MC
Marchetti
G
G
Trabattoni
D
D
Molteni
C
C
Cogliati
M
M
Bandera
A
A
Clerici
M
M
Franzetti
F
F
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016207:Cytokines / Q000096:biosynthesis* / Q000187:drug effects; D005260:Female; D018023:HIV Seronegativity / Q000276:immunology*; D006679:HIV Seropositivity / Q000150:complications / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000627:therapeutic use*; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy*; D019562:Viral Load
D000995:Antitubercular Agents; D016207:Cytokines; D013792:Thalidomide